1309377-80-7

Basic information

• Product Name: 4-(4-chloro-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-3-fluorobenzonitrile
• Synonyms: 4-(4-chloro-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-3-fluorobenzonitrile
• CAS NO: 1309377-80-7
• Molecular Weight: 290.684
• Mol File: 1309377-80-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-chloro-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-3-fluorobenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-chloro-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-3-fluorobenzonitrile(1309377-80-7)
• EPA Substance Registry System: 4-(4-chloro-6,7-dihydro-8H-pyrimido[5,4-b][1,4]oxazin-8-yl)-3-fluorobenzonitrile(1309377-80-7)

Safety Data

• Hazardous Substances Data: 1309377-80-7(Hazardous Substances Data)

Upstream product

• 107-04-0 1-Bromo-2-chloroethane 
• 63069-50-1 4-cyano-2-fluoroaniline 
• 1309377-77-2 2-[(6-chloro-5-methoxy-4-pyrimidinyl)amino]ethanol 
• 5018-38-2 4,6-dichloro-5-methoxypyrimidine 
• 64248-62-0 3,4-Difluorobenzonitrile 
• 1309377-79-4 4-chloro-7,8-dihydro-6H-pyrimidino[5,4-b][1,4]oxazine 

Downstream Products

• 1309377-53-4 C₂₅H₂₈FN₅O₅ 

Relevant articles and documents

Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-b][1,4]oxazine derivatives as potent GPR 119 agonists

GPR119 is a promising target for discovery of anti-type 2 diabetes mellitus agents. We described the optimisation of a novel series of pyrimido[5,4-b][1,4]oxazine derivatives as GPR119 agonists. Most designed compounds exhibited good agonistic activities. Among them, compound 10 and 15 demonstrated the potent EC50 values (13 and 12 nM, respectively) and strong inherent activities. Moreover, significant hypoglycaemic effect of compound 15 was observed by reducing the blood glucose AUC0–2h at the dose of 30 mg/kg, which is stronger than Vildagliptin (23.4% reduction vs. 17.9% reduction).

FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Fused Bicyclic Pyrimidine Derivatives, compositions comprising a Fused Bicyclic Pyrimidine Derivative, and methods of using the Fused Bicyclic Pyrimidine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G-protein coupled receptor (GPCR) in a patient.